Aurobindo arm gets CDSCO SEC recommendation for biosimilar

The Trastuzumab biosimilar, which is supplied in single dose glass vials containing 150 mg and 420 mg lyophilized powder concentrate for solution for infusion, is a humanised monoclonal antibody for treating metastatic breast cancer and early breast cancer that is human epidermal growth factor receptor 2 positive.

from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/M3EUA9P
via